Healthcare (SH:603313)2023-10-30 16:00Financial Performance - The company's revenue for Q3 2023 was CNY 2,114,829,072.38, representing a year-on-year increase of 6.55%[5] - The net profit attributable to shareholders for Q3 2023 was CNY 15,314,525.95, an increase of 1.50% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses for the year-to-date was CNY 125,481,490.84, showing a significant increase of 40.59%[5] - Total operating revenue for the first three quarters of 2023 was ¥5,715,461,516.09, a decrease of 5.8% compared to ¥6,067,937,202.85 in the same period of 2022[20] - Net profit for the first three quarters of 2023 was ¥126,717,884.08, an increase of 14.7% from ¥110,466,841.91 in the same period of 2022[20] - The net profit attributable to shareholders of the parent company for the first three quarters of 2023 was ¥112,930,836.10, compared to ¥98,751,538.57 in 2022, representing a growth of 14.3%[21] - The company reported a total comprehensive income of ¥146,056,115.61 for the first three quarters of 2023, compared to ¥125,173,178.59 in 2022, indicating a growth of 16.6%[21] Cash Flow - The net cash flow from operating activities for Q3 2023 was CNY 380,992,496.50, up 72.99% year-on-year[5] - The net cash flow from operating activities for Q3 2023 was ¥807,710,705.35, a significant increase from ¥240,422,909.25 in Q3 2022, representing a growth of approximately 236%[24] - The company reported a significant increase in cash flow due to reduced cash payments for goods and services[8] - Cash received from sales of goods and services in the first three quarters of 2023 was ¥5,744,293,746.23, a decrease from ¥5,970,436,436.03 in 2022, indicating a decline of 3.8%[23] - The ending balance of cash and cash equivalents as of Q3 2023 was ¥366,422,229.75, down from ¥513,407,771.14 at the end of Q3 2022, a decrease of about 29%[25] Assets and Liabilities - The total assets at the end of the reporting period were CNY 9,709,026,002.57, reflecting a year-to-date increase of 6.98%[6] - As of September 30, 2023, the total assets of the company amounted to RMB 9,709,026,002.57, an increase from RMB 9,075,676,576.56 as of December 31, 2022, reflecting a growth of approximately 7%[17] - The company's current assets totaled RMB 4,020,614,331.74, compared to RMB 3,901,852,769.55 in the previous year, indicating an increase of about 3%[17] - Total liabilities as of the end of the third quarter of 2023 amounted to ¥6,507,303,328.43, an increase from ¥6,014,473,347.87 at the end of 2022[20] - Total equity as of the end of the third quarter of 2023 was ¥3,201,722,674.14, compared to ¥3,061,203,228.69 at the end of 2022, reflecting an increase of 4.6%[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 21,072[10] - The largest shareholder, 倪张根, holds 38.60% of the shares, with 87,850,000 shares pledged[10] - The company reported a total of 187,341,715 shares held by the largest shareholder, indicating significant ownership concentration[11] Litigation and Contingent Liabilities - The company is involved in ongoing litigation with a potential liability of approximately USD 2,593.87 million, which includes punitive damages[13] - The company has confirmed a contingent liability of RMB 124,024,593.01 related to the ongoing litigation as of the reporting date[14] Research and Development - Research and development expenses for the first three quarters of 2023 were ¥82,301,362.87, compared to ¥74,781,215.10 in 2022, showing an increase of 10.3%[20] Changes in Accounting Standards - The company has implemented new accounting standards starting January 1, 2023, which may affect the financial reporting and asset valuation going forward[25]